SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon enters into strategic partnership with CytoSorbents Corporation

13 Sep 2013 Evaluate

Biocon, Asia’s largest biotech company, and CytoSorbents Corporation, based in the United States, have entered into a strategic partnership with an initial distribution agreement for India and select emerging markets, under which Biocon will have the exclusive commercialization rights for CytoSorb, a novel therapy for the management of sepsis.

Biocon and CytoSorbents will initially focus on the treatment of sepsis - the end result of an excessive immune response to infection. The effective treatment of sepsis needs to address two components - the infection and the over-activation of the immune system. By combining Biocon’s critical care antibiotics to treat the infection that are also compatible with CytoSorb therapy to modulate the immune response, the two companies will be providing the most comprehensive solution for sepsis management in the market.

CytoSorb is a safe and effective extracorporeal cytokine filter, designed to target the prevention or treatment of organ failure which is the cause of nearly half of all deaths in the intensive care unit. CytoSorb has CE Mark regulatory approval, and is clinically proven to control cytokine storm in critically-ill patients by reducing key cytokines in blood by 30-50%. It also works easily with standard dialysis machines used in hospitals.

Biocon Share Price

361.60 3.40 (0.95%)
20-Apr-2026 14:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.70
Dr. Reddys Lab 1235.90
Cipla 1232.85
Zydus Lifesciences 937.40
Lupin 2329.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×